

CITATION REPORT

List of articles citing

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

DOI: 10.1002/art.10135

Arthritis and Rheumatism, 2002, 46, 894-8.

Source: <https://exaly.com/paper-pdf/34513210/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
313	Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. <i>Arthritis and Rheumatism</i> , 2002 , 46, 851-4		66
312	Treatment of early rheumatoid arthritis. 2003 , 17, 791-809		9
311	The case against haste in the treatment of rheumatoid arthritis: comment on the editorial by Pincus et al. <i>Arthritis and Rheumatism</i> , 2003 , 48, 573-5; author reply 576-9		1
310	Reply. <i>Arthritis and Rheumatism</i> , 2003 , 48, 576-579		0
309	Understanding the window of opportunity concept in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1771-4		120
308	A view of our future: the case for redesigning rheumatology practice. <i>Arthritis and Rheumatism</i> , 2003 , 49, 716-9		9
307	Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2741-9		1246
306	Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases. 2003 , 32, 2-11		28
305	The costs of early inflammatory joint disease: a population-based study in southern Sweden. 2003 , 32, 216-24		15
304	Rheumatoid arthritis in 2003: where are we now with treatment?. 2003 , 62 Suppl 2, ii94-6		20
303	New concepts in the treatment of rheumatoid arthritis. 2003 , 54, 197-216		58
302	Clinical utility of the anti-CCP assay in patients with rheumatic diseases. 2003 , 62, 870-4		181
301	Pharmacoepidemiology and rheumatic diseases: 2001-2002. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 122-6	5.3	6
300	Methotrexate. 2003 , 15, 225-231		60
299	Genotypes and phenotypes: should genetic markers and clinical predictors drive initial treatment decisions in rheumatic diseases?. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 213-8	5.3	6
298	Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. 2004 , 63, 675-80		93
297	Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). 2004 , 63, 1085-9		259

296	Infliximab in active early rheumatoid arthritis. 2004 , 63, 149-55	179
295	Should patients with recent-onset polyarthritis receive aggressive treatment?. 2004 , 71, 475-80	23
294	Faut-il traiter de façon agressive une polyarthrite débutante ?. 2004 , 71, 854-859	
293	Du gène au problème: stratégies pour comprendre la complexité de la polyarthrite rhumatoïde. 2004 , 71, S22-S27	
292	Quelle est la place de l'etanercept dans le traitement d'une polyarthrite rhumatoïde débutante et/ou non préalablement traitée par le méthotrexate?. 2004 , 71, S34-S48	
291	Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1122-31	77
290	"The rheumatologist can see you now": Successful implementation of an advanced access model in a rheumatology practice. <i>Arthritis and Rheumatism</i> , 2004 , 51, 253-7	36
289	Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2072-81	170
288	Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2931-41	83
287	Epidemiology and burden of illness of rheumatoid arthritis. 2004 , 22, 1-12	446
286	Clinical trials in rheumatic diseases: designs and limitations. 2004 , 30, 701-24, v-vi	17
285	Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets. 2004 , 1, 289-295	5
284	Evidence for early disease-modifying drugs in rheumatoid arthritis. 2004 , 6, 15-18	5
283	Disease-modifying antirheumatic drugs: enhancing efficacy by combination. 2004 , 363, 670-1	2
282	How should we manage early rheumatoid arthritis? From imaging to intervention. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 280-5	5-3 19
281	Treatment of early rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 659-668	1
280	Quelles nouveautés dans le diagnostic et le traitement d'une polyarthrite rhumatoïde récente. 2005 , 72, 195-200	1
279	[Early diagnosis of rheumatoid arthritis]. 2005 , 64, 516-23	2

278	New concepts in the diagnosis and treatment of recent-onset polyarthritis. 2005 , 72, 119-23	6
277	[Leflunomide: assessing teratogenic risk during the first trimester of pregnancy]. 2005 , 29, 265-8	5
276	Remission in rheumatoid arthritis: wishful thinking or clinical reality?. 2005 , 35, 185-96	55
275	Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 36-41	150
274	Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3381-90	1009
273	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3333-6	37
272	A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. 2005 , 64, 38-43	49
271	Quality of life and costs for different treatment strategies for rheumatoid arthritis. 2005 , 5, 395-410	3
270	Treatment of early rheumatoid arthritis. 2005 , 15, 153-162	2
269	Tratamiento de la artritis reumatoide. 2005 , 9, 1822-1829	
268	Remodeling a rheumatology practice to facilitate early referral. 2005 , 31, 591-604	9
267	Conventional disease-modifying antirheumatic drugs in early arthritis. 2005 , 31, 729-44	14
266	Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. 2005 , 34, 359-66	56
265	Sulfasalazine: a review of its use in the management of rheumatoid arthritis. 2005 , 65, 1825-49	121
264	Has rheumatoid arthritis become a milder disease?. 2005 , 2, 331-336	1
263	Potential for altering rheumatoid arthritis outcome. 2005 , 31, 763-72	12
262	MRI and musculoskeletal ultrasonography as diagnostic tools in early arthritis. 2005 , 31, 699-714	22
261	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , 2005 , 7, R784-95	5-7 332

260	Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. 2005 , 7, R592-603	52
259	Artritis reumatoide del adulto: tratamiento. 2006 , 39, 1-26	
258	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). 2007 , 66, 34-45	508
257	Pharmacological management of transient synovitis. 2006 , 7, 35-46	
256	[Biologic therapy and infections]. 2006 , 2, 302-12	3
255	Recent evidence for the achievement of remission in rheumatoid arthritis through early aggressive therapy. 2006 , 2 Suppl 2, S18-20	
254	Tratamientos en artritis reumatoide precoz. 2006 , 7, 38-46	
253	Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. 2006 , 184, 122-5	13
252	Polyarthrite rhumatoïde de l'adulte : traitement. 2006 , 1, 1-23	1
251	HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. 2006 , 16, 615-23	67
250	[Early diagnosis of arthritis and spondyloarthritis within the framework of integrated health care in Lower Saxony]. 2006 , 65, 70-4	4
249	Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. 2006 , 26, 741-8	17
248	Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. 2006 , 26, 916-22	18
247	Current management of juvenile idiopathic arthritis. 2006 , 20, 279-300	50
246	Treating very early rheumatoid arthritis. 2006 , 20, 849-63	95
245	Acute polyarthritis. 2006 , 20, 653-72	2
244	Measuring process of arthritis care: the Arthritis Foundation® quality indicator set for rheumatoid arthritis. 2006 , 35, 211-37	35
243	The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <i>Arthritis and Rheumatism</i> , 2006 , 51, 26-37	1385

242	Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3761-73		527
241	Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 864-72		344
240	Use of biologics in rheumatoid arthritis: where are we going?. 2006 , 63, S19-41		15
239	Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. 2006 , 65, 26-9		13
238	Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics. 2006 , 65, 1102-5		25
237	Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. 2006 , 65, 45-50		31
236	New models of care for patients with rheumatoid arthritis. 2006 , 6, 159-69		2
235	Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience. 2007 , 23, 2227-34		14
234	Radiological damage in patients with rheumatoid arthritis on sustained remission. 2007 , 66, 358-63		85
233	Early rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 278-83	5-3	16
232	Pharmacogenetics in the future treatment of rheumatology. 2007 , 2, 337-339		
231	Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?. <i>Arthritis Research and Therapy</i> , 2007 , 9, 211	5-7	25
230	Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. 2007 , 3, 450-8; quiz, following 478		49
229	Changing structure and resources in a rheumatology combined unit during 1977-1999. 2007 , 36, 125-35		7
228	Change of diagnoses and outcome of patients with early inflammatory joint diseases during a mean 13-month follow-up. 2007 , 36, 194-7		7
227	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1765-75		193
226	Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2129-34		98
225	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3226-35		181

224	Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?. 2007 , 37, 601-6	8
223	Electronic and computer-generated patient questionnaires in standard care. 2007 , 21, 637-47	17
222	Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. 2007 , 37, 99-111	58
221	[Cooperation between primary care physicians and rheumatologists in Lower Saxony. Results of a survey of primary care physicians]. 2007 , 66, 142, 144-51	0
220	Kinetic modeling of contrast-enhanced MRI: an automated technique for assessing inflammation in the rheumatoid arthritis wrist. 2007 , 35, 781-95	10
219	Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. 2007 , 26, 1627-33	32
218	Induction of remission in rheumatoid arthritis: criteria and opportunities. 2008 , 29, 131-9	5
217	[Early rheumatoid arthritis]. 2008 , 49, 263-70	0
216	The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital. 2008 , 27, 1437-40	7
215	Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. 2008 , 66, 173-8	29
214	Qjust thought it was normal aches and painsQa qualitative study of decision-making processes in patients with early rheumatoid arthritis. 2008 , 47, 1577-82	62
213	Adalimumab for early rheumatoid arthritis. 2008 , 4, 157-63	2
212	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. 2009 , 1, 17-35	3
211	Coronary heart disease. 263-282	
210	Arthritis. 325-332	
209	Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. 2009 , 48, 1092-7	231
208	Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. 2009 , 48, 765-72	51
207	The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia. 2009 , 24, 260-06	4

206	Inflammatory arthritis: an overview for primary care physicians. 2009 , 121, 148-62		4
205	Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. 2009 , 38, 166-72		39
204	Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 1429-41	4.1	81
203	Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. 2009 , 48, 57-60		65
202	Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. 2009 , 38, 312-9		97
201	Improving healthcare consumer effectiveness: an Animated, Self-serve, Web-based Research Tool (ANSWER) for people with early rheumatoid arthritis. 2009 , 9, 40		11
200	Predicting the development of RA in patients with early undifferentiated arthritis. 2009 , 23, 25-36		26
199	Drug management of early rheumatoid arthritis - 2008. 2009 , 23, 93-102		14
198	Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1825-1830		63
197	Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. <i>Arthritis and Rheumatism</i> , 2009 , 61, 425-34		17
196	Cytokines as targets for anti-inflammatory agents. 2009 , 1182, 88-96		8
195	Disease-modifying antirheumatic drugs. 2009 , 34, 347-8		2
194	2. How to Use Anti-rheumatoid Drugs Including Methotrexate (MTX). 2009 , 98, 2493-2499		
193	[Novel approach for the early detection of inflammatory rheumatic diseases in the population using a mobile screening unit]. 2010 , 69, 743-8		3
192	The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. 2010 , 11, 187		21
191	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. 2010 , 24, 443-55		11
190	Predictors for remission in rheumatoid arthritis patients: A systematic review. <i>Arthritis Care and Research</i> , 2010 , 62, 1128-43	4.7	109
189	Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. <i>Arthritis Care and Research</i> , 2010 , 62, 1739-47	4.7	15

188	Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 694-704		72
187	Delay in receiving rheumatology care leads to long-term harm. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3519-21		40
186	Long-term impact of delay in assessment of patients with early arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3537-46		262
185	Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?. 2010 , 2, 307-13		3
184	The Michael Mason prize: early rheumatoid arthritis--the window narrows. 2010 , 49, 406-10		33
183	First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?. 2010 , 49, 1267-71		15
182	[Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?]. 2010 , 6, 106-10		2
181	[Role of cross-sectional imaging for early diagnosis and follow-up of rheumatoid arthritis]. 2010 , 91, 120-5		1
180	Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?. 2010 , 6, 106-110		
179	Personalized medicine: the impact on chemistry. 2010 , 1, 651-65		6
178	Management of Rheumatoid Arthritis. 2010 , 17-26		
177	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R42	5.7	160
176	Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 2068-72	4.1	32
175	[Are useful prognostic factors in rheumatoid arthritis?]. 2011 , 7, 339-42		5
174	Are Prognostic Factors Useful in Rheumatoid Arthritis?. 2011 , 7, 339-342		
173	The epidemiology of early inflammatory arthritis. 2011 , 7, 381-90		48
172	Decreasing time to treatment in rheumatoid arthritis: review of delays in presentation, referral and assessment. 2011 , 6, 173-187		
171	Treatment of early rheumatoid arthritis: concepts in management. 2011 , 40, 371-88		30

170	[Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis]. 2011 , 70, 641-50		1
169	Radiographic study on the pattern of wrist joint destruction in rheumatoid arthritis. 2011 , 30, 353-9		5
168	Impact of tight control strategy on rheumatoid arthritis in Sarawak. 2011 , 30, 615-21		1
167	The value of early intervention in RA--a window of opportunity. 2011 , 30 Suppl 1, S33-9		56
166	Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011 , 63, 675-88	4-7	33
165	Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. <i>Arthritis Care and Research</i> , 2011 , 63, 856-64	4-7	41
164	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. 2011 , 70, 1292-5		56
163	Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 2160-8	4-1	16
162	Magnetic resonance imaging of inflammatory arthropathies of peripheral joints. 2011 , 22, 45-59		10
161	Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. 2011 , 70, 500-7		162
160	Advances in early inflammatory arthritis: IP85. Genetic and Environmental Risk Factors in Early Rheumatoid Arthritis. 2011 , 50, iii21-iii22		
159	Time to treatment for new patients with rheumatoid arthritis in a major metropolitan city. <i>Journal of Rheumatology</i> , 2011 , 38, 1282-8	4-1	52
158	Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. 2011 , 40, 16-21		16
157	Who's holding up the queue? Delay in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 1225-7	4-1	3
156	Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. 2012 , 4, 149-57		43
155	Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDs. 2012 , 51, 169-75		55
154	The influence of ACPA status and characteristics on the course of RA. 2012 , 8, 144-52		144
153	Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012 , 64, 1811-8	4-7	28

152	Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2012 , 39, 2088-97	4.1	26
151	Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. 2012 , 14, 472-80		60
150	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2012-21		202
149	Inflammatory arthritis: case review and primary care perspectives. 2012 , 31, 739-44		5
148	Performance of the 2010 Rheumatoid Arthritis Classification Criteria. 2012 , 15, 455-61		4
147	Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis--a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2013 , 15, R4	5.7	47
146	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. 2013 , 11, 17		50
145	Can rheumatoid arthritis be prevented?. 2013 , 27, 467-85		35
144	A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. 2013 , 32, 665-70		16
143	Guidelines for the drug treatment of rheumatoid arthritis. 2013 , 53, 158-183		1
142	Diretrizes para o tratamento da artrite reumatoide. 2013 , 53, 158-183		16
141	Lag time between disease onset and first visit to a tertiary rheumatology centre by patients with rheumatoid arthritis. 2013 , 8, 161-164		
140	Very different performance of the power Doppler modalities of several ultrasound machines ascertained by a microvessel flow phantom. <i>Arthritis Research and Therapy</i> , 2013 , 15, R162	5.7	17
139	The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. 2013 , 72, 1420-4		46
138	Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. 2013 , 2013, 457876		14
137	Rheumatoid arthritis--early diagnosis and disease management. 2013 , 110, 477-84		32
136	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. 2013 , 72, 858-62		91
135	Assessing the need for improved access to rheumatology care: a survey of Massachusetts community health center medical directors. 2013 , 19, 361-6		7

134	Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. 2013 , 72, 1295-301		26
133	Validation of a self-administered inflammatory arthritis detection tool for rheumatology triage. <i>Journal of Rheumatology</i> , 2013 , 40, 417-24	4.1	10
132	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. 2013 , 72, 1302-7		16
131	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. 2014 , 73, 1898-904		140
130	Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?. 2014 , 66, 775-82		98
129	Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014 , 41, 2161-6	4.1	35
128	Proof-of-concept study of a Web-based methotrexate decision aid for patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1472-81	4.7	29
127	Comprehensive arthritis referral study -- phase 2: analysis of the comprehensive arthritis referral tool. <i>Journal of Rheumatology</i> , 2014 , 41, 1980-9	4.1	11
126	Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study. <i>Arthritis Care and Research</i> , 2014 , 66, 371-8	4.7	16
125	Economics of non-adherence to biologic therapies in rheumatoid arthritis. 2014 , 16, 460		39
124	Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. <i>Arthritis Research and Therapy</i> , 2014 , 16, R94	5.7	78
123	Update on research and clinical translation on specific clinical areas: From bench to bedside: How insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. 2014 , 28, 229-46		13
122	What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. 2014 , 73, 861-70		182
121	A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. 2014 , 43, 1-8		33
120	Gene expression analysis in RA: towards personalized medicine. 2014 , 14, 93-106		50
119	A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. 2014 , 15, 268		3
118	Quality of care of rural rheumatoid arthritis patients in Austria. 2014 , 126, 360-7		4
117	Review of a rheumatology triage system: simple, accurate, and effective. 2014 , 33, 247-52		11

116	Predictors of access to care in juvenile systemic lupus erythematosus: evidence from the UK JSLE Cohort Study. 2014 , 53, 557-61	8
115	Diagnostic accuracy of a clinical prediction rule (CPR) for identifying patients with recent-onset undifferentiated arthritis who are at a high risk of developing rheumatoid arthritis: a systematic review and meta-analysis. 2014 , 43, 498-507	15
114	Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. 2015 , 67, 2837-44	43
113	Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. 2015 , 74, 806-12	112
112	Advances in the management of rheumatoid arthritis. 2015 , 60, 108-14	3
111	Factors Associated With Sustained Remission in Patients With Rheumatoid Arthritis. 2015 , 11, 237-241	
110	Sonographic cutoff values for detection of abnormalities in small, medium and large joints: a comparative study between patients with rheumatoid arthritis and healthy volunteers. 2015 , 41, 989-98	10
109	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. 2015 , 54, 1640-9	12
108	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. 2015 , 1, e000057	68
107	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 2015 , 23, 231-69	300
106	The optimal combination therapy for the treatment of early rheumatoid arthritis. 2015 , 16, 1615-25	9
105	Pain and activity limitations in women and men with contemporary treated early RA compared to 10 years ago: the Swedish TIRA project. 2015 , 44, 259-64	21
104	Factors associated with sustained remission in patients with rheumatoid arthritis. 2015 , 11, 237-41	4
103	Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study. <i>Journal of Rheumatology</i> , 2015 , 42, 2279-87	4.1 24
102	Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. 2015 , 34, 221-30	19
101	Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. 2015 , 74, e12	96
100	Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. 2015 , 74, 1996-2005	40
99	Increased Kappa/Lambda Hybrid Antibody in Serum Is a Novel Biomarker Related to Disease Activity and Inflammation in Rheumatoid Arthritis. 2016 , 2016, 2953072	4

98	The Use of Avoidance, Adjustment, Interaction and Acceptance Strategies to Handle Participation Restrictions Among Swedish Men with Early Rheumatoid Arthritis. 2016 , 14, 206-218		7
97	Early rheumatoid arthritis: Clinical and functional outcomes of a cohort treated in a high complexity hospital, Cali-Colombia. 2016 , 23, 148-154		
96	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. 2016 , 46, 81-7		17
95	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. 2016 , 55, 1601-9		18
94	Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study. 2016 , 35, 1463-73		12
93	Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach. 2016 , 17, 146		27
92	Efficacy and Outcome of Rapid Access Rheumatology Consultation: An Office-based Pilot Cohort Study. <i>Journal of Rheumatology</i> , 2016 , 43, 1130-5	4.1	11
91	Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. 2016 , 23, 148-154		0
90	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. 2016 , 8, 107-18		16
89	Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. 2016 , 17, 442		19
88	Early rheumatoid arthritis: focus on RA in the developing world. 2016 , 58, 164-166		2
87	What are the effects of medication adherence interventions in rheumatic diseases: a systematic review. 2016 , 75, 667-73		56
86	Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. 2016 , 45, 171-8		15
85	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. 2016 , 55, 1177-87		27
84	Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry. 2016 , 35, 609-15		19
83	Development of Diagnostic Techniques for Early Rheumatoid Arthritis Using Positron Emission Tomography with [¹⁸ F]PK11195 and [¹⁸ F]Ketoprofen Tracers. 2017 , 19, 746-753		5
82	Qike the worst toothache youQe hadQ How people with rheumatoid arthritis describe and manage pain. 2017 , 24, 468-476		9
81	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. 2017 , 69, 1374-1380		30

80	A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?. 2017 , 36, 1215-1220		11
79	OCORRÊNCIA DE HEPATOTOXICIDADE NO TRATAMENTO DA ARTRITE REUMATOIDE INICIAL COM DMCDs SINTÉTICAS. 2017 , 57, S27-S28		
78	The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis. 2017 , 19, 66		4
77	The role of genetic analysis for predicting outcome of rheumatoid arthritis. 2017 , 17, 809-814		2
76	RESPOSTA A DMCDs SINTÉTICAS NO TRATAMENTO DA ARTRITE REUMATOIDE INICIAL. 2017 , 57, S38		
75	Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. 2017 , 18, 7		10
74	The role of ultrasound in diagnosing rheumatoid arthritis, what do we know? An updated review. 2017 , 37, 179-187		15
73	Evaluation and Differential Diagnosis of Polyarthritis. 2017 , 615-624		
72	Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis. 2017 , 12, e0182751		22
71	Early Synovitis and Early Undifferentiated Arthritis. 2017 , 1213-1220		
70	Impact of early diagnosis on functional disability in rheumatoid arthritis. 2017 , 32, 738-746		11
69	Prediction of response to methotrexate in rheumatoid arthritis. 2018 , 14, 419-429		16
68	High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. <i>Arthritis Care and Research</i> , 2018 , 70, 842-850	4-7	8
67	Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. 2018 , 21, 3-21		6
66	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. 2018 , 57, 1752-1760		9
65	Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?. <i>Arthritis Research and Therapy</i> , 2018 , 20, 15	5-7	4
64	Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 82	5-7	31
63	The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. <i>Rheumatology Advances in Practice</i> , 2019 , 3, rkz035	1-1	4

62	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. 2019 , 38, 3331-3350		11
61	Rheumatoid Arthritis Prevention: Challenges and Opportunities to Change the Paradigm of Disease Management. 2019 , 41, 1235-1239		2
60	Eight-year survival study of first-line tumour necrosis factor inhibitors in rheumatoid arthritis: real-world data from a university centre registry. <i>Rheumatology Advances in Practice</i> , 2019 , 3, rkz007	1.1	11
59	[Improvement of prognosis by timely treatment : Requirement: initial presentation within 6 weeks]. 2019 , 78, 396-403		1
58	When the first visit to the rheumatologist is established rheumatoid arthritis. 2019 , 33, 101479		3
57	Suspected very early inflammatory rheumatic diseases in primary care. 2019 , 33, 101419		
56	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2019 , 21, 243	5.7	5
55	Rheumatology Care Using Telemedicine. 2020 , 26, 335-340		17
54	Association between periodontitis and the risk of inadequate disease control in patients with rheumatoid arthritis under biological treatment. 2020 , 47, 148-159		0
53	Rheumatoid Arthritis Patient Journey: Delay in Diagnosis and Treatment. 2020 , 26, S148-S152		5
52	Ultrasound as a Biomarker in Rheumatic Diseases. 2020 , 10,		1
51	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1114-1124	4.7	2
50	[Management of early rheumatoid arthritis : Interdisciplinary guideline]. 2020 , 79, 1-38		11
49	Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial. 2020 , 99, e20824		2
48	Rural health issues in rheumatology: a review. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 119-125	5.3	8
47	A Population-Based Approach to Reporting System-Level Performance Measures for Rheumatoid Arthritis Care. <i>Arthritis Care and Research</i> , 2021 , 73, 640-648	4.7	6
46	Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients. 2021 , 24, 654-662		1
45	Influence of the rs1801274 and rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis. 2021 , 11,		1

44	Hydroxychloroquine. 2005 , 81-92	5
43	Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. 2008 , 18, 228-39	28
42	Clinical features of rheumatoid arthritis. 2011 , 829-838	4
41	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143	4
40	Rheumatoid Arthritis, Disease Modifying Agents, and Periprosthetic Joint Infection: What Does a Joint Surgeon Need to Know?. 2018 , 33, 1258-1264	23
39	Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. 2020 , 2, e332-e338	4
38	Heterogeneity of synovial molecular patterns in patients with arthritis. 2015 , 10, e0122104	21
37	[Cost analysis of treatment for severe rheumatoid arthritis in a city in southern Brazil]. 2013 , 29 Suppl 1, S81-91	4
36	Safety and efficacy of etanercept in the elderly. 2006 , 2, 189-197	2
35	Clinical utility of eco-color-power Doppler ultrasonography and contrast enhanced magnetic resonance imaging for interpretation and quantification of joint synovitis: a review. 2018 , 89, 48-77	7
34	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. 2018 , 22, 1-294	6
33	Defining Remission of Korean Patients with Rheumatoid Arthritis. 2008 , 15, 204	1
32	From Symptoms to Diagnosis: An Observational Study of the Journey of Rheumatoid Arthritis Patients in Saudi Arabia. 2016 , 31, 29-34	19
31	[Digital diagnostic support in rheumatology]. 2021 , 80, 909-913	2
30	Autoimmunity Rheumatoid Arthritis. 2005 , 481-493	
29	Targeting DMARD therapy. 2005 , 25-47	
28	Combination therapy. 2005 , 293-318	
27	[Early arthritis]. 2007 , 148, 1011-5	

- 26 Predicting the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis. **2008**, 3, 441-444
- 25 Early (Rheumatoid) Arthritis. **2009**, 73-81
- 24 RHEUMATOID ARTHRITIS. **2009**, 1025-1038
- 23 Corneal Disease in Rheumatoid Arthritis. **2011**, 1117-1132 1
- 22 Evaluation and management of early inflammatory polyarthritis. **2011**, 935-940.e3
- 21 Entzündliche Gelenkerkrankungen. **2012**, 195-399
- 20 Polyarticular Arthritis. **2013**, 587-598 1
- 19 Early Synovitis and Early Undifferentiated Arthritis. **2013**, 1161-1168
- 18 Transcriptome Profiling in Chronic Inflammatory Diseases of the Musculoskeletal System. **2014**, 195-209
- 17 Nonimmunosuppressive disease-modifying antirheumatic drugs. **2015**, 434-442 1
- 16 Evaluation and management of early inflammatory polyarthritis. **2015**, 785-789
- 15 Long-Term Outcomes in Puerto Ricans with Rheumatoid Arthritis (RA) Receiving Early Treatment with Disease-Modifying Anti-Rheumatic Drugs using the American College of Rheumatology Definition of Early RA. **2017**, 11, 136-144 3
- 14 Epidemiological Analysis and Geographical Distribution of Patients Suffering from Rheumatoid Arthritis, Eligible for First-Line Therapy/Monotherapy Treatment with Subcutaneous Formulation of Tocilizumab in the Republic of Macedonia. **2018**, 39, 69-78
- 13 Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland. *Rheumatology Advances in Practice*, **2020**, 4, rkaa059 1.1
- 12 Treatment of early rheumatoid arthritis. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 659-668
- 11 Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. *Journal of Rheumatology*, **2005**, 32, 231-8 4.1 95
- 10 Rheumatoid arthritis: previously untreated early disease. *Clinical Evidence*, **2016**, 2016, 4
- 9 Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective.. *Journal of Investigative Dermatology*, **2022**, 4.3 0

8	Healthcare disparities in telemedicine for rheumatology care.. <i>Current Opinion in Rheumatology</i> , 2022 ,	5-3	○
7	Rheumatology Continuing Professional Development for Primary Care Clinicians: A Systematic Review.. <i>Arthritis Care and Research</i> , 2022 ,	4-7	
6	Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities. <i>Cureus</i> , 2022 ,	1-2	
5	Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. <i>Arthritis Research and Therapy</i> , 2022 , 24,	5-7	○
4	Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. 2022 , 14, 1942		○
3	Adherence patterns in naïve and prevalent use of infliximab and its biosimilar. 2022 , 6,		○
2	Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis. 1-9		○
1	Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis. 2023 , 13, 61		○